It's weird, but at least guidance is intact
Two weeks after Citi doubted that Fastly's AI traffic would pay off, Oppenheimer is betting it will.
The same Medicare release sent Humana and Clover soaring.
Starbucks' turnaround is finally gaining traction, and a Chipotle deal could stall it.
An interesting - if early! - development
Two natural gas pipelines, two very different dividend checks, and one clear pick for income investors.
Nebius and CoreWeave get to raise their prices on pricier GPUs, while Oracle carries $169 billion of debt
Even Wall Street's lowest target sits above today's price
Sam Altman made safety the condition for an OpenAI listing. The man who oversaw its safety reports says they're not there yet.
Grok can lose the model race for now and SpaceX's AI business can still win
Every analyst on the stock still says Buy. The second half will show whether they're right.
In August, CSL planned to switch part of its U.S. network to Haemonetics' devices. Now it plans to switch all of it, by the end of 2027.
The Pentagon could end up owning a piece of a chipmaker that came out of bankruptcy a year ago.
Wall Street's near-term numbers barely counted on Sjögren's, so what did investors just sell?
The bigger Muse payday won't carry Muse's name.
At 5.9x forward earnings, the market is betting it won't last.
One landlord pays the bigger check with room to spare. The other has raised its dividend every year for over a decade.
Both health giants are rebuilding their insurance margins in 2026. Here's which dividend has more behind it.
Memory paid for this quarter, and a run of neocloud wins is behind next year's much bigger outlook.
But the real test starts in November.
Nearly all of Webull's revenue comes from the country now questioning who controls it.
This is good news. And it's the wrong stock regardless!
A Korean IT heavyweight just signed on, but read the fine print before you chase the jump.
One chart backs Cramer up, and another says it's still early days.
The quantum company's most important chips are leaving the lab
Spyre just added $350 million to its war chest. Here's what it cost shareholders.
Most of Wall Street's big money still doesn't own SpaceX. Which is a very good thing if you want to be early.
The CEO handoff was years in the making and the quarter came in ahead of estimates. Here's why the stock fell anyway.
